G Bradley Cole Sells 11,424 Shares of Genomic Health, Inc. (GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) CFO G Bradley Cole sold 11,424 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $57.17, for a total transaction of $653,110.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, April 9th, G Bradley Cole sold 15,000 shares of Genomic Health stock. The stock was sold at an average price of $67.61, for a total transaction of $1,014,150.00.
  • On Tuesday, March 12th, G Bradley Cole sold 15,000 shares of Genomic Health stock. The stock was sold at an average price of $75.15, for a total transaction of $1,127,250.00.

GHDX traded down $0.91 during trading on Wednesday, hitting $56.45. 197,826 shares of the company traded hands, compared to its average volume of 479,936. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of 53.76 and a beta of 0.88. Genomic Health, Inc. has a 1 year low of $36.94 and a 1 year high of $92.18. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.67 and a current ratio of 5.67.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, May 7th. The medical research company reported $0.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.05. The company had revenue of $108.80 million during the quarter, compared to analysts’ expectations of $106.75 million. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. Genomic Health’s quarterly revenue was up 17.5% on a year-over-year basis. During the same period last year, the company posted ($0.11) earnings per share. On average, equities research analysts forecast that Genomic Health, Inc. will post 1.46 earnings per share for the current year.

A number of analysts have recently issued reports on the stock. Needham & Company LLC reissued a “strong-buy” rating and issued a $97.00 price objective (up from $86.00) on shares of Genomic Health in a research note on Thursday, February 21st. ValuEngine raised shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 13th. Piper Jaffray Companies increased their price objective on shares of Genomic Health to $86.00 and gave the stock a “neutral” rating in a research note on Thursday, February 21st. BidaskClub cut shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 28th. Finally, Zacks Investment Research cut shares of Genomic Health from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. Ten investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $63.71.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Macquarie Group Ltd. increased its stake in Genomic Health by 0.5% in the 4th quarter. Macquarie Group Ltd. now owns 38,200 shares of the medical research company’s stock worth $2,461,000 after buying an additional 200 shares during the period. Royce & Associates LP increased its stake in Genomic Health by 22.8% in the 4th quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after buying an additional 273 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in Genomic Health by 166.0% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock worth $55,000 after buying an additional 493 shares during the period. Advisor Group Inc. increased its position in Genomic Health by 34.9% during the 4th quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 516 shares during the period. Finally, Quantamental Technologies LLC increased its position in Genomic Health by 19.1% during the 1st quarter. Quantamental Technologies LLC now owns 3,332 shares of the medical research company’s stock valued at $233,000 after purchasing an additional 534 shares during the period. 91.80% of the stock is owned by institutional investors.

WARNING: “G Bradley Cole Sells 11,424 Shares of Genomic Health, Inc. (GHDX) Stock” was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2019/05/16/g-bradley-cole-sells-11424-shares-of-genomic-health-inc-ghdx-stock.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

See Also: Call Option Volume

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.